ALKS Quote, Financials, Valuation and Earnings

Avadel Pharmaceuticals Plc has a net margin of 21% compared to Alkermes Plc's net margin of 0.03%. Alkermes Plc's return on equity of 22.16% beat Avadel Pharmaceuticals Plc's return on equity of -0.34%.

Alkermes Plc has a consensus price target of $43.88, signalling upside risk potential of 49.74%. On the other hand Avadel Pharmaceuticals Plc has an analysts' consensus of $20.94 which suggests that it could fall by -1.96%. Given that Alkermes Plc has higher upside potential than Avadel Pharmaceuticals Plc, analysts believe Alkermes Plc is more attractive than Avadel Pharmaceuticals Plc.

Alkermes Plc has a beta of 0.450, which suggesting that the stock is 55.029% less volatile than S&P 500. In comparison Avadel Pharmaceuticals Plc has a beta of 1.262, suggesting its more volatile than the S&P 500 by 26.242%.

Alkermes Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Avadel Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alkermes Plc pays -- of its earnings as a dividend. Avadel Pharmaceuticals Plc pays out -- of its earnings as a dividend.

Alkermes Plc quarterly revenues are $394.2M, which are larger than Avadel Pharmaceuticals Plc quarterly revenues of $77.5M. Alkermes Plc's net income of $82.8M is higher than Avadel Pharmaceuticals Plc's net income of $20K. Notably, Alkermes Plc's price-to-earnings ratio is 14.50x while Avadel Pharmaceuticals Plc's PE ratio is 299.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alkermes Plc is 3.24x versus 8.45x for Avadel Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.

CorMedix, Inc. has a net margin of 21% compared to Alkermes Plc's net margin of 49.9%. Alkermes Plc's return on equity of 22.16% beat CorMedix, Inc.'s return on equity of 95.25%.

Alkermes Plc has a consensus price target of $43.88, signalling upside risk potential of 49.74%. On the other hand CorMedix, Inc. has an analysts' consensus of $19.00 which suggests that it could grow by 84.11%. Given that CorMedix, Inc. has higher upside potential than Alkermes Plc, analysts believe CorMedix, Inc. is more attractive than Alkermes Plc.

Alkermes Plc has a beta of 0.450, which suggesting that the stock is 55.029% less volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.322, suggesting its more volatile than the S&P 500 by 32.155%.

Alkermes Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alkermes Plc pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.

Alkermes Plc quarterly revenues are $394.2M, which are larger than CorMedix, Inc. quarterly revenues of $104.3M. Alkermes Plc's net income of $82.8M is lower than CorMedix, Inc.'s net income of $108.6M. Notably, Alkermes Plc's price-to-earnings ratio is 14.50x while CorMedix, Inc.'s PE ratio is 5.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alkermes Plc is 3.24x versus 3.47x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Jazz Pharmaceuticals Plc has a net margin of 21% compared to Alkermes Plc's net margin of 22.33%. Alkermes Plc's return on equity of 22.16% beat Jazz Pharmaceuticals Plc's return on equity of -9.16%.

Alkermes Plc has a consensus price target of $43.88, signalling upside risk potential of 49.74%. On the other hand Jazz Pharmaceuticals Plc has an analysts' consensus of $208.50 which suggests that it could grow by 24.78%. Given that Alkermes Plc has higher upside potential than Jazz Pharmaceuticals Plc, analysts believe Alkermes Plc is more attractive than Jazz Pharmaceuticals Plc.

Alkermes Plc has a beta of 0.450, which suggesting that the stock is 55.029% less volatile than S&P 500. In comparison Jazz Pharmaceuticals Plc has a beta of 0.305, suggesting its less volatile than the S&P 500 by 69.522%.

Alkermes Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Jazz Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alkermes Plc pays -- of its earnings as a dividend. Jazz Pharmaceuticals Plc pays out -- of its earnings as a dividend.

Alkermes Plc quarterly revenues are $394.2M, which are smaller than Jazz Pharmaceuticals Plc quarterly revenues of $1.1B. Alkermes Plc's net income of $82.8M is lower than Jazz Pharmaceuticals Plc's net income of $251.4M. Notably, Alkermes Plc's price-to-earnings ratio is 14.50x while Jazz Pharmaceuticals Plc's PE ratio is 15.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alkermes Plc is 3.24x versus 2.45x for Jazz Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.

Perrigo Co. Plc has a net margin of 21% compared to Alkermes Plc's net margin of 1.22%. Alkermes Plc's return on equity of 22.16% beat Perrigo Co. Plc's return on equity of -0.66%.

Alkermes Plc has a consensus price target of $43.88, signalling upside risk potential of 49.74%. On the other hand Perrigo Co. Plc has an analysts' consensus of $24.50 which suggests that it could grow by 54.01%. Given that Perrigo Co. Plc has higher upside potential than Alkermes Plc, analysts believe Perrigo Co. Plc is more attractive than Alkermes Plc.

Alkermes Plc has a beta of 0.450, which suggesting that the stock is 55.029% less volatile than S&P 500. In comparison Perrigo Co. Plc has a beta of 0.386, suggesting its less volatile than the S&P 500 by 61.422%.

Alkermes Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perrigo Co. Plc offers a yield of 8.31% to investors and pays a quarterly dividend of $0.29 per share. Alkermes Plc pays -- of its earnings as a dividend. Perrigo Co. Plc pays out 94.9% of its earnings as a dividend. Perrigo Co. Plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Alkermes Plc quarterly revenues are $394.2M, which are smaller than Perrigo Co. Plc quarterly revenues of $1B. Alkermes Plc's net income of $82.8M is higher than Perrigo Co. Plc's net income of $12.7M. Notably, Alkermes Plc's price-to-earnings ratio is 14.50x while Perrigo Co. Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alkermes Plc is 3.24x versus 0.45x for Perrigo Co. Plc. Usually stocks with elevated PS ratios are considered overvalued.